Clinical Trial Update: Long-term Efficacy and Safety Extension (LTE) Study of Barzolvolimab in Participants With Chronic Spontaneous Urticaria [Phase 3]

View source ↗

Summary

A Phase 3 long-term efficacy and safety extension study of Barzolvolimab for chronic spontaneous urticaria is currently recruiting.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Spontaneous Urticaria

Drugs mentioned

• Barzolvolimab (barzolvolimab)

Snippet

Sponsor: Celldex Therapeutics | Conditions: Chronic Spontaneous Urticaria | Phase 3 | Status: RECRUITING